【摘 要】
:
Topological superconductors (TSCs) have been widely investigated in recent years due to their novel physics and ability to host Majorana fermions (MFs) which ar
【机 构】
:
School of Physical Science and Technology,ShanghaiTech University,Shanghai 201210,China;Shanghai Ins
论文部分内容阅读
Topological superconductors (TSCs) have been widely investigated in recent years due to their novel physics and ability to host Majorana fermions (MFs) which are key to topological quantum computation.Despite the great interest,only a few compounds have been proposed as candidates of intrinsic TSCs,such as iron-based superconductor FeSe0.55Te0.45 and 2M-WS2.Among them,quasi-one-dimensional superconductor TaSe3 possesses fascinating properties such as its simple stoichiometry,layered nature and chemical stability.Here,using scanning tunneling microscope/spectroscopy (STM/STS),we systematically investigate the topography and electronic structure of TaSe3.Our STM/STS measurement reveals large atomically flat,defect-free surfaces suitable for the search of MF;electronic density of states consistent with our angle-resolved photoemission result and band-structure calculations,and a uniform superconducting gap with a typical size of ~0.25 meV.Remarkably,additional edge states are observed in the vicinity of the terrace edge,suggesting they may have a topological origin.Our result proves the coexistence of superconductivity and topological electronic structure in TaSe3,making it an intriguing platform to investigate topological superconductivity.
其他文献
Ultra-thin topological insulators provide a platform for realizing many exotic phenomena such as the quantum spin Hall effect,and quantum anomalous Hall effect.
效益风险评估贯穿于药品整个的生命周期。为保障药品全生命周期最佳效益风险比,识别并针对药品风险因素采取适宜的风险最小化措施,积极开展药品上市后安全性研究尤为重要。欧洲药品管理局(European Medicines Agency,EMA)为了量化药品的安全隐患,基于评估药物的效益风险状况并支持监管决策而开展上市后安全性研究(postauthorisation safety study,PASS),为保障其顺利开展而形成一套成熟的体系及监管流程。通过分析EMA开展PASS的制度及流程,提出建立健全监管体系、制
医学文献监测指在一定范围内,收集、评估并上报待监测活性物质的不良反应报告,以提高上报不良反应报告的效率与质量,是药品不良反应(adverse drug reaction,ADR)管理和报告的重要环节。欧洲药品管理局(European Medicines Agency,EMA)是最早开展医学文献监测的机构之一,现已建立了较规范的医学文献监测方案和较为成熟的评估体系。通过介绍分析EMA医学文献监测体系,并结合我国ADR监测现状与存在的问题,从制定监测技术指南与质量管理规范、推动不良反应信息公开等方面提出政策建
We report an implementation of the momentum space quantum Monte Carlo (QMC) method on the interaction model for the twisted bilayer graphene (TBG).The long-rang
药品上市后有效性研究旨在探索药品在真实临床环境应用中产生的实际效益,是药品全生命周期监管的重要环节.欧洲药品管理局(European Medicines Agency,EMA)经过多年的探索和
1.ObjectivernLop Nur is currently one of the world 's largest playa and located in the easternmost of the Tarim Basin,northwestern China.It developed unique gia
We propose a new method to construct low-dimensional quantum devices consisting of the magnetic topological insulators.Unlike previous systems based on locally
基于生物药剂学分类系统(BCS)的生物等效性豁免旨在减少对体内生物等效性研究的需求,即可以提供一种体内生物等效性的替代方法。基于BCS分类的生物等效性豁免需提供药物的溶解性、渗透性和体外溶出数据。主要论述药物溶解性、渗透性和体外溶出度测定的方法,希望建立药物相关特性的标准化、规范化测定流程,以保证企业在申报生物等效性豁免时,所提供的数据是准确、可靠的。
在仿制药研究过程中通过体外评价方法替代体内生物等效性研究可以减少临床资源消耗,加快药品上市进度,这是基于生物药剂学分类系统(BCS)的生物等效性豁免的主要原因。随着我国仿制药的快速发展,企业基于BCS的生物豁免申请需求越来越迫切,当药物制剂为具有全身作用的普通口服制剂,且药物活性成分符合溶解性和渗透性(BCS I和III类)标准,受试制剂剂型和规格与参比制剂相同,可适用基于BCS的生物等效性豁免。对国内外的基于BCS分类的生物豁免研究进展和法规进行综述,并对具体操作及申报要求提出一些思考。
Near-bottom observation data from the manned deep submersible Jiaolong with high-precision underwater positioning data from Weijia Guyot,Magellan Seamounts in the Western Pacific Ocean are reported.Three substrate types were identified:Sediment,ferromanga